3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Carcinoma, Renal Cell
1
Adenoma, Islet Cell
1
Interventions
Everolimus
6
Sunitinib
3
Octreotide
3
cabozantinib
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Injections
2
Fluorouracil
2
Capecitabine
2
Bevacizumab
2
recombinant interferon alpha 2b-like protein
1
pentetreotide
1
pasireotide
1
motesanib diphosphate
1
lanreotide
1
ibrutinib
1
ganitumab
1
gallium Ga 68 dotatate
1
fludarabine phosphate
1
belzutifan
1
batifiban
1
atezolizumab
1
abemaciclib
1
X-Rays
1
Thalidomide
1
Temozolomide
1
Streptozocin
1
Sorafenib
1
Phantoms, Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
belzutifan
×
Endocrine
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA